Jun 2026 (Q2 FY26) — Aug 12, 2026
Fortress Biotech Q2 FY26 — Journey Medical Delivers Positive Adjusted EBITDA on Accelerating Emrosi Adoption
Read the full callFortress Biotech (FBIO) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Fortress Biotech earnings: last reported Wed, 12 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 18.7 | +14.0% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | -53.5 | +168.8 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | -0.47 | −103.0% YoY | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. |
Price
$1.87 0.00% · $0
Performance −30.7% 1Y
1Y: $2.7 on 17 Oct 2025 → $1.87. High $4.38 (8 Jan 2026), low $1.87 (16 Oct 2026).
- Previous close
- $1.87
- 52-week range
- $1.87 – $4.38
- One year
- −32.25%
Overview
- Symbol
- FBIO
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
Fortress Biotech earnings calls (FBIO)
Financials
What the filings say
Net profit, year on year: −103% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 15 | 15 | 13 | 16 | 18 | 16 | 16 | 19 |
| Expenses | 37 | 39 | 35 | 53 | 24 | — | 24 | 29 |
| Operating profit | -22 | — | -22 | -36 | -7 | — | -8 | -10 |
| Operating margin | −151.0% | — | −169.8% | −222.2% | −38.6% | — | −48.3% | −53.5% |
| Other income | -5 | -2 | -2 | 25 | 16 | -1 | 150 | 11 |
| Profit before tax | -27 | -26 | -25 | -12 | 9 | — | 142 | 1 |
| Tax rate | −0.3% | — | 0.0% | 0.0% | 0.3% | — | 3.6% | 34.7% |
| Net profit | -13 | -7 | -11 | 15 | 6 | -4 | 110 | -0 |
| EPS ($ per share) | -0.76 | — | -0.48 | 0.50 | 0.13 | — | 3.44 | -0.08 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves | -396 | -436 | -483 | -547 | -634 | -695 | -741 | -734 |
| Total liabilities | 121 | 154 | 136 | 171 | 244 | 166 | 146 | 123 |
| Fixed assets | 12 | 12 | 12 | 15 | 13 | 7 | 3 | 3 |
| Investments | 18 | 0 | — | — | — | — | — | — |
| Total assets | 141 | 226 | 333 | 397 | 294 | 168 | 144 | 186 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -99 | -95 | -84 | -117 | -179 | -128 | -80 | -66 |
| Cash from investing | 19 | 20 | -7 | 41 | -23 | -2 | -15 | 10 |
| Cash from financing | 51 | 147 | 172 | 149 | 75 | 33 | 71 | 77 |
| Net cash flow | -29 | 72 | 82 | 73 | -127 | -98 | -25 | 22 |
| Capital expenditure | -7 | -2 | -2 | -5 | -3 | -0 | 0 | — |
| Free cash flow | -106 | -97 | -86 | -121 | -182 | -128 | -80 | — |
Insider filings
10 filings between Jan 1, 2026 and Oct 1, 2026.
Open market
decisions to buy or sellNobody bought or sold FBIO on the open market in this window. The filings below are 10 awards.
Compensation
not trading decisions- 10
- Award — granted as compensation
Latest filings (23)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Oct 1, 2026 | Jin David Chief Financial Officer | Award | 1,190 | $2.2K |
| Jun 22, 2026 | Jin David Chief Financial Officer | Award | 400,000 | $0 |
| Apr 1, 2026 | Jin David Chief Financial Officer | Award | 2,967 | $6.5K |
| Mar 18, 2026 | WEISS MICHAEL S Executive Vice Chairman | Award | 475,424 | $0 |
| Mar 18, 2026 | ROSENWALD LINDSAY A MD PRESIDENT, CEO & CHAIRMAN | Award | 475,424 | $0 |
| Jan 1, 2026 | Hoenlein Malcolm Director | Award | 27,322 | $0 |
| Jan 1, 2026 | Harvey Jimmie Director | Award | 27,322 | $0 |
| Jan 1, 2026 | Klein Dov Director | Award | 27,322 | $0 |
| Jan 1, 2026 | Lorenz Kevin Director | Award | 27,322 | $0 |
| Jan 1, 2026 | LOBELL J JAY Director | Award | 27,322 | $0 |
| Oct 1, 2025 | Jin David Chief Financial Officer | Award | 2,711 | $3.5K |
| Apr 1, 2025 | Jin David Chief Financial Officer | Award | 5,000 | $6.1K |
| Jan 1, 2025 | ROSENWALD LINDSAY A MD PRESIDENT, CEO & CHAIRMAN | Award | 454,153 | $0 |
| Jan 1, 2025 | Hoenlein Malcolm Director | Award | 49,383 | $0 |
| Jan 1, 2025 | Lorenz Kevin Director | Award | 49,383 | $0 |
| Jan 1, 2025 | Harvey Jimmie Director | Award | 49,383 | $0 |
| Jan 1, 2025 | Lu Lucy Director | Award | 49,383 | $0 |
| Jan 1, 2025 | Klein Dov Director | Award | 49,383 | $0 |
| Jan 1, 2025 | LOBELL J JAY Director | Award | 49,383 | $0 |
| Jan 1, 2025 | WEISS MICHAEL S Executive Vice Chairman | Award | 454,153 | $0 |
| Dec 19, 2024 | Jin David Chief Financial Officer | Award | 1,000,000 | $0 |
| Oct 1, 2024 | Jin David Chief Financial Officer | Award | 2,625 | $3.2K |
| Sep 23, 2024 | ROSENWALD LINDSAY A MD PRESIDENT, CEO & CHAIRMAN | Purchase | 763,359 | $1.40M |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for Fortress Biotech, Inc.
Free account. Everything above stays public.
Write why you follow Fortress Biotech, Inc. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading